开发并验证单心室心脏病一期姑息术后间期死亡或移植风险评分
本研究基于美国国家儿科心脏病质量改进协作组2008至2015年注册数据,分析2128例需弓部重建的单心室先心病患儿,主要终点为间期死亡或移植。在学习队列(三分之二患者)中通过多因素logistic回归和分类回归树分析建立加权风险评分(NEONATE评分,0-76分),并在验证队列中验证,两队列准确率均超过75%。验证队列中评分>17分的患者事件率接近≤17分患者的3倍。
要点
- NEONATE评分用于一期姑息术后预测间期死亡或移植,准确率>75%。
- 评分>17分者间期事件率约为≤17分者的3倍。
- 评分纳入7项因素:Norwood类型、术后ECMO、出院带阿片类、出院未用狄高辛、术后弓部梗阻、无氧需求的中重度三尖瓣反流、中重度三尖瓣反流需额外吸氧。
核心结论
- NEONATE风险评分可用于一期姑息术后预测间期死亡或移植,学习队列和验证队列准确率均超过75%。
- 验证队列中评分>17分的患者间期事件率接近评分≤17分患者的3倍。
研究设计与样本
- 回顾性分析美国国家儿科心脏病质量改进协作组注册数据,纳入2008至2015年需弓部重建的单心室先心病患儿2128例。
- 以三分之二患者为学习队列,采用多因素logistic回归和分类回归树分析建立风险评分,其余患者为验证队列进行验证。
- 主要复合终点为间期死亡或移植。
主要发现
- 总体事件率为9%(153例[7%]死亡,42例[2%]移植)。
- 学习队列中独立相关因素包括:Norwood类型、术后ECMO、出院带阿片类、出院未用狄高辛、术后弓部梗阻、无氧需求的中重度三尖瓣反流、中重度三尖瓣反流需额外吸氧。
- 基于上述因素构建加权风险评分NEONATE(0-76分),学习队列和验证队列准确率均超过75%。
关键数值与推荐
- NEONATE评分范围0-76分,准确率>75%。
- 验证队列中评分>17分患者事件率接近≤17分患者的3倍。
临床怎么用
- 可在一期姑息术后使用NEONATE评分识别间期死亡或移植高风险患儿,评分>17分者需加强监测与干预。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To develop a risk score to predict mortality or transplant in the interstage period. BACKGROUND: The "interstage" period between the stage 1 and stage 2 palliation is a time of high morbidity and mortality for infants with single-ventricle congenital heart disease. METHODS: This was an analysis of patients with single-ventricle congenital heart disease requiring arch reconstruction who were enrolled in the National Pediatric Cardiology Quality Improvement Collaborative registry from 2008 to 2015. The primary composite endpoint was interstage mortality or transplant. Multivariable logistic regression and classification and regression tree analysis were performed on two-thirds of the patients ("learning cohort") to build a risk score for the composite endpoint, that was validated in the remaining patients ("validation cohort"). RESULTS: In the 2128 patients analyzed in the registry, the overall event rate was 9% (153 [7%] deaths, 42 [2%] transplants). In the learning cohort, factors independently associated with the composite endpoint were (1) type of Norwood; (2) postoperative ECMO; (3) discharge with Opiates; (4) No Digoxin at discharge; (5) postoperative Arch obstruction, (6) moderate-to-severe Tricuspid regurgitation without an oxygen requirement, and (7) Extra Oxygen required at discharge in patients with moderate-to-severe tricuspid regurgitation. This model was used to create a weighted risk score ("NEONATE" score; 0-76 points), with >75% accuracy in the learning and validation cohorts. In the validation cohort, the event rate in patients with a score >17 was nearly three times those with a score ≤17. CONCLUSIONS: We introduce a risk score that can be used post-stage 1 palliation to predict freedom from interstage mortality or transplant.
引用
- Ahmed H, Anderson JB, Bates KE, et al. Development of a validated risk score for interstage death or transplant after stage I palliation for single-ventricle heart disease. J Thorac Cardiovasc Surg. 2019. PMID: 31924360. doi:10.1016/j.jtcvs.2019.11.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。